One of the enduring qualities of successful leaders and entrepreneurs is strong and unshakable belief and passion for success and mission of the business. Clay Siegall, the cofounder of Seattle Genetics, is one such leader and entrepreneur with strong passion and unshakable belief in the company and its staff. Under his leadership, Seattle Genetics has made significant steps towards developing effective targeted cancer treatment therapies. Within its current drugs portfolio, the company has an FDA-approved conjugate drug for targeted treatment of cancer. This is in addition to several others in the pipeline currently being developed in partnership with well known pharmaceutical companies including Bayer and Pfizer.
Siegall’s passion stems from personal experience after watching one of his relatives go through the traumatizing experience of conventional cancer treatment. This inspired him early on as a university student to seek for alternative and effective treatment options. Under his leadership, Seattle Genetics has made significant strides despite challenging financial times. The company generates revenues from the sale of its drugs, technological licensing and strategic partnerships. The company has a strong sales and legal team, which identifies business opportunities and negotiates the company’s deals and partnerships. His success boils down to hard work and strong passion in his dream of better targeted treatment of cancer.
Scholarly Background and Passion for Targeted Cancer Treatment
Clay Siegall has made a name for himself within the academic and business circles as a scion of impassioned dedication to developing effective targeted cancer treatment therapies. He graduated from the University of Maryland with a Bachelor of Science degree in zoology. He is also an alumnus of George Washington University where he graduated with a Doctor of Philosophy in genetics.
Before cofounding Seattle Genetics in 1998, he worked as a research scientist for several organizations. Over the years, he has authored several publications primarily on cancer. He is an award-winning inventor with 15 patents to his name. He is currently serving as the company’s chief executive officer, president and chairman of its board of directors. He also serves on the board of several companies and editorial boards of some journals. Over the years, he has helped in raising over a billion dollars to help the company in funding research and development of technology-based treatment for cancer.